SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage
Retrieved on:
Tuesday, August 2, 2022
Biomedical Advanced Research and Development Authority, Education, BARDA, NIH, ASPR, Bacteria, Bill, Bill & Melinda Gates Foundation, NIAID, Boston University, Twitter, Human, United States patent law, CEO, Lymphatic system, Development, National Institute, Partnership, IP, Cas9, Office of Inspector General, U.S. Department of Health and Human Services, Infection, Patent, Federal Ministry of Health (Germany), CRISPR, National Institute of Allergy and Infectious Diseases, Social, Assistant, Cas3, Clinical trial, Human services, Technology, FDA, Boston University School of Law, Patient, LinkedIn, BMBF, Annual report, Therapy, 2020–2021 Thai protests, Office of the Assistant Secretary for Preparedness and Response, Communication, USPTO, Cas, Pharmaceutical industry, Research, Wellcome
SNIPR Biome is the first company to orally dose humans with a CRISPR therapeutic and SNIPR001 has been granted Fast-Track designation by the FDA.
Key Points:
- SNIPR Biome is the first company to orally dose humans with a CRISPR therapeutic and SNIPR001 has been granted Fast-Track designation by the FDA.
- The new patent covers lytic phage armed with CRISPR gene editing systems.
- CRISPR and phage lysis of target bacteria is a potent combination for therapeutics, and the patent includes the use of any CRISPR system, for example, Cas9, Cas3, or any other Cas nuclease.
- The new patent adds to the companys extensive patent estate protecting this technology, including granted patent number US10,920,222 with a fundamental scope protecting fast and durable action of CRISPR targeting in E coli.